fasudil has been researched along with Anoxemia in 26 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to investigate the mechanism of fasudil alleviating hypoxic pulmonary hypertension (HPH)." | 7.83 | Fasudil alleviated hypoxia-induced pulmonary hypertension by stabilizing the expression of angiotensin-(1-7) in rats. ( Fu, EQ; Li, ZC; Liu, ML; Wang, YX; Zhang, B, 2016) |
| "To investigate whether right ventricular hypertrophy in hypoxic pulmonary hypertension (HPH) rats could be prevented by treatment with Rho kinase inhibitor fasudil." | 7.81 | Effect of fasudil on hypoxic pulmonary hypertension and right ventricular hypertrophy in rats. ( Li, SY; Sun, XZ; Tian, XY; Wu, QQ, 2015) |
| "The aim of this study was to investigate the effects of Rho kinase inhibitor-Fasudil on hypoxic pulmonary hypertension (HPH) and pulmonary vascular remodeling in rats." | 7.80 | Effects of fasudil on hypoxic pulmonary hypertension and pulmonary vascular remodeling in rats. ( Li, J; Sun, XZ; Tian, XY; Wang, DW, 2014) |
| " Monocrotaline (MCT)-induced and chronic hypoxia-induced PH models of rats were established, and the haemodynamic and pathomorphologic results of three different doses of fasudil (10 mg/kg, 30 mg/kg, and 75 mg/kg per day) were subsequently compared with those of bosentan (30 mg/kg per day)." | 7.80 | Fasudil reversed MCT-induced and chronic hypoxia-induced pulmonary hypertension by attenuating oxidative stress and inhibiting the expression of Trx1 and HIF-1α. ( Chen, S; Dong, K; Li, Z; Liu, M; Wang, Y; Zhang, B; Zheng, L; Zheng, W, 2014) |
| " Here, we used the model of hypoxia/reoxygenation (H/R) injury to explore the possibility whether Fasudil, a ROCK inhibitor in clinical application for subarachnoid hemorrhage and stroke, mobilizes adult neural stem cells in vivo." | 7.76 | Fasudil, a Rho kinase inhibitor, drives mobilization of adult neural stem cells after hypoxia/reoxygenation injury in mice. ( Ding, J; Li, QY; Lu, CZ; Sun, CH; Wang, X; Xiao, BG; Yu, JZ, 2010) |
| " The rats were exposed to10% hypoxia for 3 weeks to establish a PAH model, which showed an increase in right ventricle systolic pressure, right ventricular and pulmonary vascular remodeling, and the accelerated senescence and impaired functions in EPCs, accompanied by an increase in Rho-kinase (ROCK) and NOX activities, p-nmMLC20 level, NOX expression and H2O2 content; these phenomena were reversed by fasudil, a selective inhibitor of ROCK." | 3.83 | Non-muscle myosin light chain promotes endothelial progenitor cells senescence and dysfunction in pulmonary hypertensive rats through up-regulation of NADPH oxidase. ( Gong, ZC; Li, T; Liu, B; Liu, WQ; Luo, XJ; Ma, QL; Peng, J; Peng, JJ; Zhang, JJ, 2016) |
| "The aim of this study was to investigate the mechanism of fasudil alleviating hypoxic pulmonary hypertension (HPH)." | 3.83 | Fasudil alleviated hypoxia-induced pulmonary hypertension by stabilizing the expression of angiotensin-(1-7) in rats. ( Fu, EQ; Li, ZC; Liu, ML; Wang, YX; Zhang, B, 2016) |
| "To investigate whether right ventricular hypertrophy in hypoxic pulmonary hypertension (HPH) rats could be prevented by treatment with Rho kinase inhibitor fasudil." | 3.81 | Effect of fasudil on hypoxic pulmonary hypertension and right ventricular hypertrophy in rats. ( Li, SY; Sun, XZ; Tian, XY; Wu, QQ, 2015) |
| "The aim of this study was to investigate the effects of Rho kinase inhibitor-Fasudil on hypoxic pulmonary hypertension (HPH) and pulmonary vascular remodeling in rats." | 3.80 | Effects of fasudil on hypoxic pulmonary hypertension and pulmonary vascular remodeling in rats. ( Li, J; Sun, XZ; Tian, XY; Wang, DW, 2014) |
| " Monocrotaline (MCT)-induced and chronic hypoxia-induced PH models of rats were established, and the haemodynamic and pathomorphologic results of three different doses of fasudil (10 mg/kg, 30 mg/kg, and 75 mg/kg per day) were subsequently compared with those of bosentan (30 mg/kg per day)." | 3.80 | Fasudil reversed MCT-induced and chronic hypoxia-induced pulmonary hypertension by attenuating oxidative stress and inhibiting the expression of Trx1 and HIF-1α. ( Chen, S; Dong, K; Li, Z; Liu, M; Wang, Y; Zhang, B; Zheng, L; Zheng, W, 2014) |
| " Here, we used the model of hypoxia/reoxygenation (H/R) injury to explore the possibility whether Fasudil, a ROCK inhibitor in clinical application for subarachnoid hemorrhage and stroke, mobilizes adult neural stem cells in vivo." | 3.76 | Fasudil, a Rho kinase inhibitor, drives mobilization of adult neural stem cells after hypoxia/reoxygenation injury in mice. ( Ding, J; Li, QY; Lu, CZ; Sun, CH; Wang, X; Xiao, BG; Yu, JZ, 2010) |
| "Recently, fasudil, a Rho kinase (ROCK) inhibitor, was reported to prevent cerebral ischemia in vivo by increasing cerebral blood flow and inhibiting inflammatory responses." | 3.74 | Fasudil, a Rho kinase (ROCK) inhibitor, protects against ischemic neuronal damage in vitro and in vivo by acting directly on neurons. ( Hara, H; Iwama, T; Kotani, Y; Nakajima, Y; Nakashima, S; Shimazawa, M; Yamashita, K; Yoshimura, S, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (46.15) | 29.6817 |
| 2010's | 13 (50.00) | 24.3611 |
| 2020's | 1 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Hilal, TA | 1 |
| Hossain, MA | 1 |
| Alobaida, A | 1 |
| Alam, F | 1 |
| Keshavarz, A | 1 |
| Nozik-Grayck, E | 1 |
| Stenmark, KR | 1 |
| German, NA | 1 |
| Ahsan, F | 1 |
| Wang, ZH | 1 |
| Zhu, D | 1 |
| Xie, S | 1 |
| Deng, Y | 1 |
| Pan, Y | 1 |
| Ren, J | 1 |
| Liu, HG | 1 |
| Rothschild, PR | 1 |
| Salah, S | 1 |
| Berdugo, M | 1 |
| Gélizé, E | 1 |
| Delaunay, K | 1 |
| Naud, MC | 1 |
| Klein, C | 1 |
| Moulin, A | 1 |
| Savoldelli, M | 1 |
| Bergin, C | 1 |
| Jeanny, JC | 1 |
| Jonet, L | 1 |
| Arsenijevic, Y | 1 |
| Behar-Cohen, F | 1 |
| Crisanti, P | 1 |
| Li, JR | 1 |
| Zhao, YS | 1 |
| Chang, Y | 1 |
| Yang, SC | 1 |
| Guo, YJ | 1 |
| Ji, ES | 1 |
| Li, C | 1 |
| Liu, PP | 1 |
| Tang, DD | 1 |
| Song, R | 1 |
| Zhang, YQ | 1 |
| Lei, S | 1 |
| Wu, SJ | 1 |
| Toba, M | 1 |
| Alzoubi, A | 1 |
| O'Neill, KD | 1 |
| Gairhe, S | 1 |
| Matsumoto, Y | 1 |
| Oshima, K | 1 |
| Abe, K | 2 |
| Oka, M | 3 |
| McMurtry, IF | 3 |
| Sun, XZ | 3 |
| Tian, XY | 2 |
| Wang, DW | 2 |
| Li, J | 2 |
| Liu, M | 1 |
| Wang, Y | 1 |
| Zheng, L | 1 |
| Zheng, W | 1 |
| Dong, K | 1 |
| Chen, S | 1 |
| Zhang, B | 2 |
| Li, Z | 1 |
| Li, SY | 1 |
| Wu, QQ | 1 |
| Liu, B | 1 |
| Li, T | 1 |
| Peng, JJ | 1 |
| Zhang, JJ | 1 |
| Liu, WQ | 1 |
| Luo, XJ | 1 |
| Ma, QL | 1 |
| Gong, ZC | 1 |
| Peng, J | 1 |
| Zychowski, KE | 1 |
| Lucas, SN | 1 |
| Sanchez, B | 1 |
| Herbert, G | 1 |
| Campen, MJ | 1 |
| Wang, YX | 1 |
| Liu, ML | 1 |
| Fu, EQ | 1 |
| Li, ZC | 1 |
| Badejo, AM | 1 |
| Dhaliwal, JS | 1 |
| Casey, DB | 1 |
| Gallen, TB | 1 |
| Greco, AJ | 1 |
| Kadowitz, PJ | 1 |
| Huang, L | 1 |
| Li, Q | 1 |
| Li, H | 1 |
| He, Z | 1 |
| Cheng, Z | 1 |
| Chen, J | 1 |
| Guo, L | 1 |
| Ding, J | 2 |
| Yu, JZ | 2 |
| Li, QY | 2 |
| Wang, X | 2 |
| Lu, CZ | 2 |
| Xiao, BG | 2 |
| Sun, CH | 1 |
| Xu, EZ | 1 |
| Kantores, C | 1 |
| Ivanovska, J | 1 |
| Engelberts, D | 1 |
| Kavanagh, BP | 1 |
| McNamara, PJ | 1 |
| Jankov, RP | 1 |
| Nagaoka, T | 1 |
| Fagan, KA | 1 |
| Gebb, SA | 1 |
| Morris, KG | 2 |
| Suzuki, T | 1 |
| Shimokawa, H | 2 |
| Rikitake, Y | 1 |
| Kim, HH | 1 |
| Huang, Z | 1 |
| Seto, M | 1 |
| Yano, K | 1 |
| Asano, T | 1 |
| Moskowitz, MA | 1 |
| Liao, JK | 1 |
| Weigand, L | 1 |
| Sylvester, JT | 1 |
| Shimoda, LA | 1 |
| Guilluy, C | 1 |
| Sauzeau, V | 1 |
| Rolli-Derkinderen, M | 1 |
| Guérin, P | 1 |
| Sagan, C | 1 |
| Pacaud, P | 1 |
| Loirand, G | 1 |
| Tawara, S | 1 |
| Oi, K | 1 |
| Hizume, T | 1 |
| Uwatoku, T | 1 |
| Fukumoto, Y | 1 |
| Kaibuchi, K | 1 |
| Homma, N | 1 |
| Taraseviciene-Stewart, L | 1 |
| Kraskauskas, D | 1 |
| Burns, N | 1 |
| Voelkel, NF | 1 |
| Yamashita, K | 1 |
| Kotani, Y | 1 |
| Nakajima, Y | 1 |
| Shimazawa, M | 1 |
| Yoshimura, S | 1 |
| Nakashima, S | 1 |
| Iwama, T | 1 |
| Hara, H | 1 |
| Broughton, BR | 1 |
| Walker, BR | 1 |
| Resta, TC | 1 |
26 other studies available for fasudil and Anoxemia
| Article | Year |
|---|---|
Design, synthesis and biological evaluations of a long-acting, hypoxia-activated prodrug of fasudil, a ROCK inhibitor, to reduce its systemic side-effects.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Endothelial Cells; Humans; Hypoxia; Prodrugs; Protein | 2021 |
Inhibition of Rho-kinase Attenuates Left Ventricular Remodeling Caused by Chronic Intermittent Hypoxia in Rats via Suppressing Myocardial Inflammation and Apoptosis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Apoptosis; Hypoxia; Inflammation; Male; Myoc | 2017 |
ROCK-1 mediates diabetes-induced retinal pigment epithelial and endothelial cell blebbing: Contribution to diabetic retinopathy.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Animals; Biomarkers; Case-Control Studies; Cyto | 2017 |
Fasudil improves endothelial dysfunction in rats exposed to chronic intermittent hypoxia through RhoA/ROCK/NFATc3 pathway.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Aorta; Endothelin-1; Endothelium, Vascular; | 2018 |
Targeting the RhoA-ROCK pathway to regulate T-cell homeostasis in hypoxia-induced pulmonary arterial hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Hypertension, Pulmonary; Hypoxia; Interleuki | 2018 |
Temporal hemodynamic and histological progression in Sugen5416/hypoxia/normoxia-exposed pulmonary arterial hypertensive rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiogenesis Inhibitors; Animals; Familial Primary Pu | 2014 |
Effects of fasudil on hypoxic pulmonary hypertension and pulmonary vascular remodeling in rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Arterioles; Blood Pressure; Carotid Arteries | 2014 |
Fasudil reversed MCT-induced and chronic hypoxia-induced pulmonary hypertension by attenuating oxidative stress and inhibiting the expression of Trx1 and HIF-1α.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Analysis of Variance; Animals; Disease Models, Animal | 2014 |
Effect of fasudil on hypoxic pulmonary hypertension and right ventricular hypertrophy in rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Heart; Hypertension, | 2015 |
Non-muscle myosin light chain promotes endothelial progenitor cells senescence and dysfunction in pulmonary hypertensive rats through up-regulation of NADPH oxidase.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cellular Senescence; Endothelial Progenitor | 2016 |
Hypoxia-induced pulmonary arterial hypertension augments lung injury and airway reactivity caused by ozone exposure.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Air Pollutants; Animals; Bronchial Hyperreactivity; B | 2016 |
Fasudil alleviated hypoxia-induced pulmonary hypertension by stabilizing the expression of angiotensin-(1-7) in rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiotensin I; Animals; Gene Expression; Hypertension | 2016 |
Analysis of pulmonary vasodilator responses to the Rho-kinase inhibitor fasudil in the anesthetized rat.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13 | 2008 |
Inhibition of intracellular Ca2+ release by a Rho-kinase inhibitor for the treatment of ischemic damage in primary cultured rat hippocampal neurons.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adenosine Triphosphate; Animals; Calcium; Cells, Cult | 2009 |
Rho kinase inhibitor Fasudil induces neuroprotection and neurogenesis partially through astrocyte-derived G-CSF.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Antibodies, Neutralizing; Astrocytes; Cell C | 2009 |
Fasudil, a Rho kinase inhibitor, drives mobilization of adult neural stem cells after hypoxia/reoxygenation injury in mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult Stem Cells; Animals; Antibodies; Astrocytes; Br | 2010 |
Rescue treatment with a Rho-kinase inhibitor normalizes right ventricular function and reverses remodeling in juvenile rats with chronic pulmonary hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Age Factors; Aging; Amides; Animals; Apoptosis; Cell | 2010 |
Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Inhalation; Administration, Oral; Ami | 2005 |
Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Analysis of Variance; Animals; Antihypertensi | 2005 |
Mechanisms of endothelin-1-induced contraction in pulmonary arteries from chronically hypoxic rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13 | 2006 |
Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actins; Animals; Carrier Proteins; Chronic Disease; C | 2005 |
Long-term inhibition of Rho-kinase ameliorates hypoxia-induced pulmonary hypertension in mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Arterioles; Blotting, Western; Disease Model | 2006 |
[Effects of intervention with Rho kinase inhibitor fasudil on rats with hypoxic pulmonary hypertension].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Hypertension, Pulmonary; Hypoxia; Protein Ki | 2006 |
Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Disease Progression; | 2007 |
Fasudil, a Rho kinase (ROCK) inhibitor, protects against ischemic neuronal damage in vitro and in vivo by acting directly on neurons.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain Ischemia; Cell Survival; Dose-Response | 2007 |
Chronic hypoxia induces Rho kinase-dependent myogenic tone in small pulmonary arteries.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Endothelium, Vascular; Hypoxia; Male; Muscle | 2008 |